Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Quantitative efficacy of L-carnitine supplementation on glycemic control in type 2 diabetes mellitus patients.

  • 2021-04-29
  • Expert review of clinical pharmacology 14(7)
    • Dong-Dong Wang
    • Yi-Zhen Mao
    • Su-Mei He
    • Yang Yang
    • Xiao Chen

Study Design

Type
Meta-Analysis
Population
type 2 diabetes mellitus patients
Methods
model-based meta-analysis (MBMA); data extracted from public database; maximal effect (E_max) models with nonlinear mixed effects modeling (NONMEM)
Duration
treatment duration to reach half of the maximal effects (ET_50) were 36.1 weeks (FPG) and 106 weeks (HbA1c)

Objectives

This study aimed to explore the quantitative efficacy of L-carnitine supplementation on glycemic control in type 2 diabetes mellitus patients using model-based meta-analysis (MBMA).

Methods

Literatures were retrieved from the public database and data from these trials were extracted. The quantitative efficacy of L-carnitine on fasting plasma glucose (FPG) and glycated hemoglobin (HbA1c) in type 2 diabetes mellitus patients were evaluated by maximal effect (Emax) models with nonlinear mixed effects modeling (NONMEM).

Results

In the model of FPG, Emax and treatment duration to reach half of the maximal effects (ET50) were -9.8% and 36.1 weeks, respectively. In the model of HbA1c, Emax and ET50 were -19.6% and 106 weeks, respectively. In addition, the durations for achieving 25%, 50%, 75%, 80%, and 90% Emax of L-carnitine on FPG were 13, 36.1, 118, 160, and 390 weeks, respectively. The durations for achieving 25%, 50%, 75%, 80%, and 90% Emax of L-carnitine on HbA1c were 38, 106, 334, 449, and 1058 weeks, respectively.

Conclusions

It was the first time to provide valuable quantitative information for efficacy of L-carnitine supplementation on glycemic control in type 2 diabetes mellitus patients.

Research Insights

Back to top